Management of R/R Myeloma: Clinical, Economic, and Patient-Centric Strategies for Managed Care

Join us in Chicago or via simulcast for this 1.5 hour live, interactive CPE-certified program led by pharmacy experts discussing optimal managed care pharmacy approaches for managing patients with relapsed or refractory multiple myeloma.

To Register: On the Event Dates page click a date/time, click blue Register button in upper right-hand corner. Once registered, you will receive a reminder email with a link to join in advance of the Webinar.

ProCE, LLC and Clinical Care Options, LLC are committed to providing a safe and healthy environment for all our learners. Our decisions and preventive measures are guided by the requirements and recommendations of the CDC alongside federal, state, and local health authorities. We work with each program venue to implement preventive measures to reduce the potential spread of COVID-19. Additionally, in accordance with AMCP’S COVID-19 protocols, all in-person learners will be asked to wear a mask and present their AMCP’S conference badge -OR- proof of vaccination AND Government-issued ID to gain admittance to The Evolving Management of Relapsed/Refractory Myeloma: Clinical, Economic, and Patient-Centric Strategies for Managed Care Pharmacy Professionals.

For more information on AMCP’s vaccination and mask requirements, please visit: AMCP’S website

*If you do not have your vaccination record card, find out other ways to verify you have been vaccinated.

Agenda

  • Welcome and Program Overview
  • Navigating the Current Treatment Algorithm for R/R MM
    • Overview of current treatment options at first relapse
    • New indications and approvals: Optimizing integration into current algorithms
    • Monitoring for and managing adverse events
  • On the Horizon: Emerging Therapies for R/R MM
  • Managed Care Strategies for Patient Engagement, Quality Care, and Optimizing Treatment
  • Outcomes

Events

Date / Time
Event Details

Faculty

Faculty
Rebecca Gonzalez, PharmD, BCOP

Clinical Pharmacist
Blood and Marrow Transplant/Cellular Immunotherapy
Department of Pharmacy
Moffitt Cancer Center
Tampa, Florida

Faculty
Bhavesh Shah, RPh, BCOP

Chief Pharmacy Officer
Department of Pharmacy
Boston Medical Center Health System
Boston, Massachusetts

Program Overview
Join us in Chicago or via simulcast for this live, interactive CPE-certified program led by Rebecca Gonzalez, PharmD, BCOP, and Bhavesh Shah, RPh, BCOP, discussing optimal managed care pharmacy approaches for managing patients with relapsed or refractory multiple myeloma.

Goal Statement
The goal of this activity is to improve the knowledge, confidence, and competence of learners in the management of patients with relapsed/refractory multiple myeloma.

Target Audience
The target audience for this activity is pharmacists, including managed care, specialty, and clinical pharmacists, who care for patients with relapsed/refractory multiple myeloma as well as pharmacy directors, chief pharmacy officers, and other stakeholders in pharmacy practice.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Recognize approved and emerging therapeutic strategies for patients with relapsed/refractory multiple myeloma to aid the interprofessional, collaborative care team in treatment decision making using available data and patient-related and disease-related factors
  • Develop an understanding of the mechanisms of action of and clinical trial findings with recently FDA-approved novel therapies to facilitate optimal integration into treatment algorithms/clinical pathways
  • Assist the interprofessional, collaborative care team in the supportive care of patients with relapsed/refractory multiple myeloma through early detection and management of treatment-related adverse events
  • Identify ways managed care pharmacists can promote optimal clinical integration of approved and emerging therapeutic strategies for patients with relapsed/refractory multiple myeloma to reduce associated costs, decrease hospitalization, and improve outcomes for patients

Accreditation

CE Accreditation

Pharmacists

ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-0000-22-095-L01-P has been assigned to this live application-based activity (initial release date 3-31-2022). This activity is approved for 1.5 contact hours (0.15 CEU) in states that recognize ACPE providers. The activity is provided at no cost to participants. Participants must complete the online post-test and activity evaluation within 30 days of the activity to receive pharmacy CE credit. No partial credit will be given. Statements of completion will be issued online at www.ProCE.com, and proof of completion will be posted in NABP CPE Monitor profiles.

Disclosure
ProCE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to ProCE policy. ProCE is committed to providing its learners with high-quality CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company. Faculty disclosures will be provided prior to the start of the CE activity.